DIAGNOSTIC TEST OF POLYNEUROPATHY SCORE, 10-G SENSSES WENSTEIN MONOFILAMENT (SWM) AND VIBRATION PERCEPTION TRESHOLD (VPT)-QUANTITATIVE SENSORY TESTING (QST) IN DISTAL SENSORY POLYNEUROPATHY (DSP)-HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Bethasiwi Purbasari¹, Shahdevi Nandar Kurniawan¹, Machlusil Husna¹, Didi Candradikusuma², Harun Al-Rasyid³

Correspondence: bethasiwi@gmail.com
¹Department of Neurology Faculty of Medicine Brawijaya University, Malang, Indonesia.
²Department of Internal Medicine Faculty of Medicine Brawijaya University, Malang, Indonesia.
³Department of Public Health Faculty of Medicine Brawijaya University, Malang, Indonesia.

ABSTRACT

Background: HIV/AIDS is a worldwide pandemic. Peripheral neuropathy is the most common neurologic complication with distal sensory polyneuropathy (HIV-DSP) as the most frequent form of manifestation. HIV-DSP is one of the major causes of global pain morbidity and often undiagnosed, resulting in treatment given when HIV-DSP grade is already severe. Early detection is imperative to prevent the progression of HIV-DSP and improve patient’s quality of life. Polyneuropathy score, 10-g Semmes-Weinstein Monofilament (SWM) and vibration perception threshold (VPT)-quantitative sensory testing (QST) are considered to be potential candidates for HIV-DSP screening tool.

Objective: To measure the reability of Polyneuropathy Score, SWM and VPT- QST in diagnosing HIV-DSP.

Methods: This research is a descriptive study with cross-sectional design. Research was conducted on 77 patients of HIV/AIDS outpatient clinic in RS Saiful Anwar (RSSA) during November 2016 - April 2017 (n = 77). Patients were screened for HIV-DSP by using polyneuropathy score, such as: Michigan Neuropathy Screening Instrument (MNSI), Toronto Clinical Scoring System (TCSS), Brief Peripheral Neupropathy Score (BPNS), SWM, and VPT-QST. Sensitivity, specificity, positive predictive value and negative predictive value of BPNS, TCSS, MNSI, SWM and VPT-QST are analyzed using cross tabulation. Area under receiver operating characteristic (ROC) curve analysis was used to measure diagnostic accuracy of each tools. SPSS 19.0 was used for statistical analysis.

Results: TCSS had a sensitivity, specificity, positive predictive value, negative predictive value positive likelihood ratio, negative likelihood ratio, and accuracy as much as: 70%, 97%, 97%, 74%, 23.33, 0.28 and 83%. The result of TCSS analysis using ROC showed that TCSS had excellent diagnostic value with AUC (Area Under Curve) of 0.89 (95%CI 82%-96.5%). The AUC of BPNS score, monofilament and VPT-QST respectively: 0.469, 0.194, and 0.189.

Conclusion: The result of the HIV-DSP diagnostic test using TCSS score has the best value compared to other tools.

Keywords: Distal Sensory Polyneuropathy HIV, TCSS, MNSI, BPNS, SWM, VPT-QST

Introduction

Human Immunodeficiency Virus (HIV) had become a worldwide pandemic with global prevalence of 36.9 million people living with HIV with two million new cases each year.¹² In 2009, an estimate of 186,000 people in Indonesia is HIV positive.³ Papua, Jakarta, and Bali are Indonesia’s three provinces with the highest new HIV infection cases in 2011.³ Peripheral neuropathy is one of the most commonly found neurologic complication in HIV infection yet frequently remain undiagnosed, resulting in inadequate treatment.⁵,⁶ However, increased life expectancy from ARV therapy leads to increased prevalence of peripheral neuropathy due to longer duration of HIV infection and toxicity of ARV medications on peripheral nerves.⁶ From six HIV-associated peripheral neuropathy clinical manifestation, the most prevalent neurologic complication is distal sensory polyneuropathy (HIV-DSP).⁷

Prevalence rate of HIV-DSP varied worldwide with estimated range of 27%-57%, where 38%-90% HIV-DSP patients experienced neuropathic pain.⁸¹¹ HIV-DSP neuropathic pain is frequently debilitating and adversely impacting patients’ quality of life,¹² also relatively difficult
to treat. As a result, HIV-DSP become one of the major causes of global pain morbidity. Early recognition of signs and symptoms of HIV-DSP is imperative to prevent the progression and to improve patients’ quality of life. Unfortunately, HIV-DSP frequently undiagnosed in early stages, resulting in treatment provided when HIV-DSP grade is already severe.

Until today, there had been no gold standard diagnostic testing for establishing HIV-DSP diagnosis. Nerve conduction velocity (NCV) test using electroneuromyography (ENMG), quantitative sensory test (QST), and intra epidermal nerve fiber (IENF) density assessment had been heavily investigated and proven to assist in HIV-DSP diagnosis. The aforementioned tests are not feasibly conducted for early screening HIV-DSP to all HIV patients due to the high cost and relatively lengthy period of test. Thus, the need for a simple, easy, effective, and efficient test to diagnose HIV-DSP in its early stage.

Several diagnostic tests had been proposed as distal sensory polyneuropathy early screening instrument in various cases worldwide, such as Polyneuropathy Scoring using Brief Peripheral Neuropathy Screen (BPS), Toronto Clinical Scoring System (TCSS), and Michigan Neuropathy Screening Instrument (MNSI). Also monofilament examination using 10-g Semmes-Weinstein Monofilament (SWM). Meanwhile, DSP diagnostic modality using easily-used diagnostic instrument such as portable quantitative sensory testing (QST) had been validated in numerous research studies. However, there had been no research comparing the diagnostic reliability of these screening instruments to ENMG in detecting HIV-DSP.

The objective of this research is to determine the reliability of HIV-associated distal sensory neuropathy (HIV-DSP) diagnostic screening instruments, SWM, and VPT-QST compared to NCV testing using ENMG in RSU Saiful Anwar (RSSA) Malang.

Methods

Design

This research is designed as an observational research using cross sectional method.

Location and Timing

This research was conducted in tropical infection clinic Saiful Anwar General Hospital Malang from November 2016 to June 2017 upon receiving approval from Saiful Anwar General Hospital Malang Ethical Committee.

Population and Sample

The participant of this research are patients meeting inclusion and exclusion criteria, using purposive sampling. Inclusion criteria for this research are patients with confirmed HIV diagnosis based on the following 3 (three) methods, Reagen SD Bioline HIV 1/2 3.0, Intec One Step Anti-HIV (1&2), and Oncoprobe, patients with confirmed DSP diagnosis based on clinical examination and ENMG, aged between 18-64 years old, and gave informed consent to participate in polyneuropathy scoring examination, SWM, VPT-QST and ENMG. Exclusion criteria for this research are patients with lower limbs defect, pregnant, suffering from chronic illness, suffering from cardiovascular disease (hypertension, coronary disease, and history of stroke), history of cancer and/or chemoterapy, history of alcohol consumption, history of tuberculosis medication in the last 6 (six) months, history of diabetes, contraindication to electrodiagnostic examination, neurological deficit, absence of peripheral artery disease indicated by pulsation detection of a.dorsalis pedis, and patients not giving informed consent to participate in polyneuropathy scoring examination, SWM, VPT-QST and ENMG.

Variable Definition

Brief Peripheral Neuropathy Screen (BPNS)

A DSP scoring tool consisted of 3 (three) main components: symptoms experienced by patients, vibration perception test using tuning fork, and achilles tendon reflex testing. BPNS score 0=no DSP (normal), BPNS score 1-3=mild DSP (grade 1), BPNS score 4-6=moderate DSP (grade 2), BPNS score 7-10=severe DSP (grade 3).

Toronto Clinical Scoring System (TCSS)

A DSP scoring tool consisted of 3 (three) components, symptom scores, reflex scores, and sensory test scores. Score ≤5 no neuropathy, score 6-8=mild neuropathy, score 9-11=moderate neuropathy and score ≥12 indicated severe neuropathy.

Michigan Neuropathy Screening Instrument (MNSI)

A DSP scoring tool consisted of 2 (two) components, symptoms experienced by patients and physical examination by medical professional. MNSI score ≥9.5 (7 on questionnaire and 2.5 on physical examination) indicated DSP.

10-g Semmes-Weinstein Monofilament (SWM)

A cutaneous sensation evaluation using 5.07 gauge Semmes Weinstein monofilament fiber (with 10 grams of force to buckle) on 9 spots at plantar pedis and 1 spot at dorsum pedis. Abnormal result defined by failure to detect pressure in ≥4 sites.

Vibration perception threshold (VPT) – quantitative sensory testing (QST)

A quantitative sensory testing to determine patient’s ability to detect vibration perception threshold with predefined intensity. The vibratory transducer was placed on the dorsal surface of the great toe. The output is categorized according to pre-programmed degree of abnormality, adjusted to patient’s age. Normal range=8-12, abnormal range=0-7.

Confirmed HIV-DSP

Presence of polyneuropathy signs or symptoms started in distal body parts, symmetrically appeared, and abnormality in ENMG test.

HIV-DSP degree defined as follows: a. Mild: pinprick diminished at the tip of the toes or vibration detected for 5-10 seconds at the great toe. Moderate: pinprick diminished to the ankles or vibration detected for <5 seconds at the great toe. Severe: pinprick diminished past the ankles or no vibration detected at the great toe. Electroneuromyography test performed by testing the sural, median, and ulnar sensory nerves and testing the tibialis posterior, peroneal, median, and ulnar motor nerves. Test performed by neurophysiology professional using Nihon Kohden/Neuropack M1 MEB-9200 version 08.06 (copyright 1997-2007) at electrophysiology laboratory.
RSSA Malang. To prevent bias, participants’ identity is restricted during NCV test.

**Procedure and Workflow**

At the beginning stage of research, patients completed a form containing required data for this research. Data required including patients’ identity, short anamnesis to obtain information on risk factors, duration of HIV, duration of ARV therapy, types of medication consumed, associated comorbidities (hypertension, history of stroke, coronary disease, metabolic syndrome), other neuropathy risk factors (malnutrition, vitamin B12 deficiency, history of cancer and/or chemotherapy, history of alcohol consumption, history of neurotoxic medications, and history of peripheral nerve entrapment. Afterwards, vital sign examination (blood pressure, pulse, and respiratory rate), internal status examination, and neurological status examination are performed. Subsequently, an examination to eliminate peripheral neuropathy due to nerve entrapment by performing provocative maneuvers, consisted of Lasegue, Bragard, Sicard, Valsalva, Lhermitte, and Spurling.

The next step is to determine whether patients meeting the inclusion criteria. Patients meeting the inclusion criteria further eliminated using exclusion criteria. The remaining patients that are willing to participate asked to fill out informed consent form. Afterwards, HIV-DSP signs and symptoms clinical examination is performed. Upon encountering abnormality, further procedure of neuropathy scoring consisted of BPNS, TCSS, and MNSI is performed. Upon completion, subsequent procedure of 10-g Semmes-Weinstein Monofilament (SWM) using neuropen (Owen Mumford, LTD) at plantar pedis and dorsum pedis and vibration perception threshold (VPT) – quantitative sensory testing (QST) using Nervecheck (Phi Med Europe S.L. Barcelona, Spain) at distal lower extremity. Upon completion of preceding DSP tests, nerve conduction velocity test to confirm HIV-DSP diagnosis is performed using electroneuromyography (Nihon Kohden/Neuropack M1 MEB-9200 version 08.06). All tests performed by trained medical professional and the result of all test are recorded and documented for further analysis.

**Data Analysis**

Data obtained in this research is statistically analyzed using SPSS 19.0. Data analysis required are sensitivity, specificity, positive predictive value and negative predictive value of BPNS, TCSS, MNSI, SWM and VPT-QST compared to NCV-ENMG using cross tabulation (2x2). Under the curve receiver operating characteristic (ROC) area analysis also performed to compare diagnostic accuracy of each HIV-DSP diagnostic tool.

**Results**

**Subject Characteristic**

This research involved 77 patients meeting inclusion criteria, not meeting exclusion criteria, and able to participate throughout the whole research duration as research subject. HIV-DSP prevalence were detected in 53% of the patients, with 21% mild neuropathy, 21% moderate neuropathy and 11% severe neuropathy. Percentage of HIV patients with no HIV-DSP based on predetermined diagnosis criteria is 47%.

Basic profile of polyneuropathy HIV-DSP patients in this research is shown in Table 1 below. Average patients age is 35.08 years old for normal group and 39.22 years old for HIV-DSP group. Average time since HIV diagnosis is 1.92 years for normal group and 2.20 years for HIV-DSP group. Average duration of ARV therapy is 1.60 years for normal group and 1.82 years for HIV-DSP group. Average CD4 nadir count is 443 cells/mm³ for normal group and 141.46 cells/mm³ for HIV-DSP group. Average current CD4 count is 463.83 cells/mm³ for normal group and 228.95 cells/mm³ for HIV-DSP group. Male-female proportion between two groups are similar with 18:18 for normal group and 17:24 for group with HIV-DSP. Smoker and non-smoker patient proportion varies between the two groups, with 2:34 for normal group and 12:29 for group with HIV-DSP.

**Table 1. Basic Profile of HIV-DSP Patients Analysis Result.**

| Basic Data                    | Normal (n=36) | HIV- DSP (n=41) |
|-------------------------------|---------------|----------------|
| Age (years)                   | 35.08 ±9.07   | 39.22 ±10.79   |
| HIV duration (years)          | 1.92 ±2.18    | 2.20 ±1.85     |
| ARV therapy duration (years)  | 1.60 ±2.14    | 1.82 ±1.80     |
| Body Mass Index               | 20.90 ±3.49   | 21.85 ±4.23    |
| CD4 Nadir (average±stdev)     | 443.00 ±508.73 | 141.46 ±156.63 |
| CD4 (average±stdev)           | 463.83 ±123.62 | 228.95 ±131.44 |
| Sex (female, male)            | 18:18         | 17:24          |
| Smoking (positive,negative)   | 2:34          | 12:29          |

**HIV-DSP Result Using Polyneuropathy Diagnostic Scoring, Monofilament and VPT-QST Test**

HIV-DSP prevalence using BPNS score, MNSI score, TCSS score, monofilament and VPT-QST test compared to actual HIV-DSP are shown in Figure 1. The highest HIV-DSP prevalence is from BPNS score at 76.62% while the lowest is from MNSI score at 25.97%. HIV-DSP prevalence using monofilament and VPT-QST is similar at 41.56% while TCSS score results at 38.96%.
Figure 1. HIV-DSP Prevalence Test Result Using BPNS Score, Michigan Score (MNSI), TCSS Score, Monofilament (SWM) and VPT-QST Test.

Cross tabulation of BPNS score, MNSI score, TCSS score, Monofilament and VPT-QST Examination are shown in Table 2. Based on the table, sensitivity value for BPNS is 100%, with 50% specificity, 69% positive predictive value, 100% negative predictive value, positive likelihood ratio of 2.0, negative likelihood ratio of 0, and 77% accuracy. Meanwhile sensitivity value for MNSI is 46%, with 97% specificity, 95% positive predictive value, 61% negative predictive value, positive likelihood ratio of 15.3, negative likelihood ratio of 0.03, and 70% accuracy. TCSS sensitivity value is 70%, with 97% specificity, 97% positive predictive value, 74% negative predictive value, positive likelihood ratio of 23.33, negative likelihood ratio of 0.28, and 83% accuracy. As for monofilament, sensitivity value is 66%, with 86% specificity, 84% positive predictive value, 69% negative predictive value, positive likelihood ratio of 7.1, negative likelihood ratio of 0.39, and 77% accuracy. Lastly, sensitivity value for VPT-QST is 73%, with 94% specificity, 94% positive predictive value, 76% negative predictive value, positive likelihood ratio of 12.16, negative likelihood ratio of 0.29, and 83% accuracy.

Table 2. Cross Tabulation of BPNS Score, MNSI Score, TCSS Score, Monofilament and VPT-QST Test.

|                | HIV-DSP | Non HIV-DSP |
|----------------|---------|-------------|
| BPNS Score     | 41      | 18          |
| MNSI Score     | 19      | 1           |
| TCSS score     | 29      | 1           |
| SWM            | 27      | 5           |
| VPT-QST        | 30      | 2           |

Diagnostic test result of BPNS Score, TCSS score, Monofilament and VPT-QST using Receiver Operating Curve (ROC) shown below in Figure 2. AUC value for BPNS is 46.9%, TCSS is 89.3%, Monofilament is 19.4% and VPT-QST is 18.9%. The expected AUC is 60%. 

A

B
Figure 2. ROC Analysis Result for BPNS Score (A), TCSS Score (B), Monofilament (C) and VPT-QST Test (D).

The overall comparison of DSP-HIV diagnostic test using BPNS score, MNSI score, TCSS score, Monofilament and VPT-QST test is presented in Table 3.

Table 3. Comparison of DSP-HIV Diagnostic Test Using BPNS Score, MNSI Score, TCSS Score, Monofilament and VPT-QST Test.

| Diagnostic Tool | Sens | Spec | PPV | NPV | Acc | AUC |
|-----------------|------|------|-----|-----|-----|-----|
| BPNS            | 100% | 50%  | 69% | 100%| 77% | 46.9%|
| MNSI            | 46%  | 97%  | 95% | 61% | 70% | -    |
| TCSS            | 70%  | 97%  | 97% | 74% | 83% | 89.3%|
| SWM             | 66%  | 86%  | 84% | 69% | 75% | 19.4%|
| VPT-QST         | 73%  | 94%  | 94% | 76% | 83% | 18.9%|

Abbreviations: Sens: Sensitivity; Spec: Specificity; PPV: Positive Predictive Value; NPV: Negative Predictive Value; Acc: Accuracy; AUC: Area Under the Curve

Discussion

This research is conducted by performing HIV-DSP screening on HIV patients treated in infection clinic RSU Saiful Anwar Malang, with total sample of 77 patients. Based on PNP criteria from AAN, AAEM and AAPM&R, HIV-DSP prevalence were detected in 53% of the patients, with 21% mild neuropathy, 21% moderate neuropathy and 11% severe neuropathy. Average patient age is 35.08 years old for normal group and 39.22 years old for HIV-DSP group, with no significant age difference between the two groups. The average age of patients with HIV-DSP in this research is similar with other research where the average age of patients with HIV-DSP is 31.81 years old for group without neuropathy and 34.11 years old for group with neuropathy. Male-female proportion between the two groups is similar with 18:18 for normal group and 17:24 for group with HIV-DSP. It is generally consistent with other research, where there were no significant difference in sex percentage of HIV-DSP patients. Average years since HIV diagnosis is 1.92 years for normal group and 2.20 years for HIV-DSP group. Research conducted by Konchalard, et. al. showed average years since HIV diagnosis is 3.2 years for normal group and 3.7 years for group with HIV neuropathy, with no significant difference between the two group. Body mass index for both group is relatively similar, with 20.9 for normal group and 21.85 for HIV-DSP group, consistent with other research, where there is no significant BMI difference between neuropathy group dan non-neuropathy HIV group.

Average CD4 nadir count is 443 cells/mm3 for normal group and 141.46 cells/mm3 for HIV-DSP group. The result is relatively consistent with other research, where CD4 nadir count is 256 cells/mm3 for group without HIV neuropathy and 96 cells/mm3 for group with HIV neuropathy, indicating significant CD4 nadir count difference between two groups. Average current CD4 count is 463.83 cells/mm3 for normal group and 228.95 cells/mm3 for HIV-DSP group. This result is also consistent with other research, where significant current CD4 count difference between group without HIV neuropathy and group with HIV neuropathy is observed.

This research screened HIV-DSP using BPNS score, MNSI score, TCSS score, monofilament test using 10-g Semmes Weinsteins, and vibration perception using VPT-QST. HIV-DSP prevalence comparison in this research using BPNS score, MNSI score, TCSS score, monofilament test, and VPT-QST test with gold standard of diagnosis criteria and ENMG were as follows 76.62%, 25.97%, 38.96%, 41.56%, 41.56% and 53.25%. HIV-DSP prevalence using BPNS score at 76.62% is relatively high compared to gold standard. This result was possibly due to the high sensitivity of this tool, thus patients with minimum clinical...
condition is classified in HIV-DSP group while the clinical signs and ENMG test shown normal result.

This research shown the following values for BPNS score: sensitivity is 100%, 50% specificity, 69% positive predictive value, 100% negative predictive value, positive likelihood ratio of 2.0, negative likelihood ratio of 0, and 77% accuracy. BPNS diagnostic result using Receiver Operating Curve (ROC) shown Area Under Curve (AUC) value of 0.469 (95% CI 33.22%-60.6%), sig value 0.639. AUC value of 46.9% translated to where BPNS is used to diagnose neuropathy in 100 HIV patients, 47 patients will have confirmed diagnosis. Based on its confidence interval, AUC value for BPNS in population ranged from 33.22% to 60.6%. From statistical perspective, the value is considered as unsatisfactory. The result is relatively different from other research where BPNS diagnostic values for HIV-DSP were as follows: Sensitivity is 17-18%, 93-94% specificity, 10-37% positive predictive value, 84-96% negative predictive value, positive likelihood ratio of 2.45-2.75, negative likelihood ratio of 0.88-0.89, and 80-89% accuracy. Meanwhile BPNS AUC from the research were at 0.553-0.554. The different diagnostic test result were possibly due to substantial difference in sample size. This research sample size is 77 patients while research by Cettomai, et al., recorded sample size of 240 patients. The significant sample size difference considered to be the cause of BPNS diagnostic values for HIV-DSP result difference.

For MNSI score, the values for HIV-DSP diagnostic test are as follows: sensitivity is 46%, 97% specificity, 95% positive predictive value, 61% negative predictive value, positive likelihood ratio of 15.3, negative likelihood ratio of 0.03, and 70% accuracy. As of today, MNSI score had never been utilized to diagnose HIV-DSP, and only used as screening method for patients with polyneuropathy diabetes mellitus (PNP-DM). Several research reported MNSI score sensitivity value at 61%, 79% specificity, 55% positive predictive value, and negative predictive value at 83%. The difference of diagnostic value were possibly due to different sample size and different distal sensory neuropathy examined.

The values for HIV-DSP diagnostic test for monofilament test are as follows: sensitivity is 66%, 86% specificity, 84% positive predictive value, 69% negative predictive value, positive likelihood ratio of 7.1, negative likelihood ratio of 0.39, and 77% accuracy. Monofilament test diagnostic result using Receiver Operating Curve (ROC) shown unsatisfactory diagnostic value due to less than 50% line curve value. The resulting Area Under Curve (AUC) value is 0.194 (95% CI 5.9%-23.9%), sig value 0.000. From statistical perspective, the value is considered as unsatisfactory. Monofilament test AUC value was possibly due to significant difference in sample size and different characteristics of research sample. The sample size for this research is 77 patients, while the sample size for research conducted by Cettomai, et al., was 238 patients. The sample size difference is considered to be a major factor in VPT-QST AUC result difference.

The values for HIV-DSP diagnostic test for VPT-QST test are as follows: sensitivity is 73%, 94% specificity, 94% positive predictive value, 76% negative predictive value, positive likelihood ratio of 12.16, negative likelihood ratio of 0.29, and 83% accuracy. VPT-QST diagnostic result using Receiver Operating Curve (ROC) shown unsatisfactory diagnostic value for VPT-QST due to less than 50% line curve value. The resulting Area Under Curve (AUC) value from ROC method is 0.194 (95% CI 5.9%-23.9%), sig value 0.000. From statistical perspective, the value is considered as unsatisfactory. AUC value of 18.9% translated to if VPT-QST used to diagnose neuropathy in 100 HIV patients, 19 patients will have confirmed diagnosis. Based on its confidence interval, VPT-QST AUC value in population ranged from 5.9% to 23.9%. Hypothesis testing performed by comparing AUC result with AUC value of 50%. The resulting Sig value of <0.05 shown significant difference with AUC value of 50%. From clinical perspective, VPT-QST AUC value is unsatisfactory by not meeting the expected AUC value of 60%. Cross tabulation diagnostic test result shown similar result with other research, where the result for VPT-QST HIV-DSP diagnostic values are as follows: Sensitivity at 56%, 81% specificity, 38% positive predictive value, 90% negative predictive value, positive likelihood ratio of 2.91, negative likelihood ratio of 0.54, and 76% accuracy. Meanwhile, AUC value for QST-PVT for the research is 0.684. Different AUC value was possibly due to significant difference in sample size and different characteristics of research sample. The sample size for this research is 77 patients, while the sample size for research conducted by Cettomai, et al., was 238 patients. The sample size difference is considered to be a major factor in VPT-QST AUC result difference.

HIV-DSP diagnostic test result using TCSS score shown highest accuracy compared to other tools. The values for HIV-DSP diagnostic test for TCSS score are as follows: sensitivity is 77%, 97% specificity, 97% positive predictive value, 74% negative predictive value, positive likelihood ratio of 23.33, negative likelihood ratio of 0.28, and 83% accuracy. TCSS score analysis result shown excellent diagnostic value due to higher than 50% line curve value. The resulting Area Under Curve (AUC) value is 0.893 (95% CI 82%-96.5%), sig value 0.000. From statistical perspective, the value is considered as satisfactory. AUC value of 89.3% translated to if TCSS score utilized to diagnose neuropathy in 100 HIV patients, 89 patients will have confirmed diagnosis. Based on its confidence interval, TCSS score AUC value in population ranged from 82% to 96.5%. Hypothesis testing performed by comparing AUC result with AUC value of 50%. The resulting Sig
value of <0.05 shown significant difference with AUC value of 50%. From clinical perspective, TCSS AUC value is satisfactory by exceeding the expected AUC value of 60%. TCSS score diagnostic result is generally similar with other research where TCSS score sensitivity and specificity value for HIV-DSP is 79% with AUC value of 0.87.²⁷

The relatively high positive predictive value and negative predictive value from screening tools used in this research shown that positive diagnostic result majorly resulted from true positive data while negative diagnostic result majorly resulted from true negative data. In this research, the accuracy of neuropathy test score consisted of HIV-DSP signs and symptoms such as TCSS is better in diagnosing HIV-DSP compared to single modality test such as Monofilament and vibration sensation test with VPT-QST. Diagnostic test using Monofilament and vibration sensation test with VPT-QST shown similar result. This result is consistent with research conducted by Meijer et. al., where test using tuning fork resulted in similar validity and positive predictive value with Monofilament test, even produced similar result with SWM test combined with PNP-DM test score.³⁸⁻⁴⁰

TCSS shown the highest diagnostic value for HIV-DSP and can be reliably used as DSP screening tool on HIV patients. A follow up research with bigger sample size and more specific sample criteria is needed to evaluate the value of other diagnostic tools.

This research’s applicability is limited to HIV patients similar to this research population setting and not generalized to wider HIV patients population.

**Conclusion**

TCSS shown the highest diagnostic value for detecting HIV-DSP compared to other tests. The highest accuracy were shown by TCSS and VPT-QST at 83% and highest AUC value shown by TCSS at 89.3%.

**Acknowledgement**

The author thanks to the Brawijaya University and Saiful Anwar General Hospital, Malang, East Java, Indonesia for facilitating this research.

**References**

1. World Health Organization. World Health Observatory (WHO) Data: HIV/AIDS. www.who.int/gho/hiv/en/. Accessed on 7 May 2016, 09.35
2. Joint United Nations Programme on HIV/AIDS. Global report 2012: Unaids report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS, 2013
3. Kementerian Kesehatan Republik Indonesia – Direktorat Jeneral Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman nasional tatalaksana klinis infeksi hiv dan terapi antiretroviral; 2011,1-2
4. Unicef Indonesia. Responding to hiv and aids. issue briefs; oktober 2012, 1-3
5. Letendre SL, Ellis RJ, Everall I, Ances B, Bharti A, McCutchan. A. neurologic complications of hiv disease and their treatment. international aids society-usa: topics in hiv medicine; 2009:46-56. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19401607
6. Duarte AG, Papp JR, Simpson DM. Diagnosis and management of hiv-associated neuropathy. Neurou Clin 26, Elsevier saunders; 2008:821-832. DOI: 10.1016/j.ncl.2008.04.001
7. Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep; 2012:16:226-36. DOI: 10.1007/s11916-012-0257-z
8. Beadles WL, Jahn A, Weigel R, Clutterbuck D. Peripheral neuropathy in hiv-positive patients at an antiretroviral clinic in lilongwe, malawi. Trop Doet; 2009:39:78-80. DOI: https://doi.org/10.1258/td.2008.080213
9. Morgello S, Estanislaio L, Simpson D, Geraci A., DiRocco A., Gerita P. Manhattan hiv brain bank. hiv-associated distal sensory peripheral neuropathy in the era of highly active antiretroviral therapy. the manhattan hiv brain bank. Arch Neurol; 2004:61:153-161
10. Shikuma C, Gerschenson M, Ananworanich J, Valeour V, Teeratakulpisarn N, Jadwattanakul T, et al. SEARCH 003 protocol team. Determinants of epidermal nerve fiber density in antiretroviral-naive HIV-infected individuals. HIV Med; 2012:13:602-608
11. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaidya F, Collier A., Marra CM, Ances B, Atkinson JH, Dworkin RH, Morgello S, Grant I. Continued high prevalence and adverse clinical impact of human immunodeficiency virus associated sensory neuropathy in the era of combination antiretroviral therapy: the charter study. Arch Neurol; 2010:67: 552-58. DOI: 10.1001/archneurol.2010.76
12. Maritz J, Benatar M, Dave JA., Harrison TB, Badri M, Levitt NS, Heckmann JM. HIV neuropathy in south african: frequency, characteristics, and risk factors. Muscle Nerve; 2010:41:599-606. DOI: 10.1002/mus.21535
13. Keltner JR, Vaidya F, Ellis RJ, Moeller-Bertram T, Fitzsimmons C, Duarte NA, Robinson-Papp J, Dworkin RH, Clifford DB, Mcarthur JC, Simpson DM, Collier AC, Marra CM, Atkinson JH, Grant I. Health-related quality of life 'well-being' in hiv distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics; 2012:53:380-86
14. Phillips TJ, Cherryl CL, Cox S, Marshall SJ, Rice ASC. Pharmacological treatment of painful hiv-associated sensory neuropathy: a systematic review and metaanalysis of randomized controlled trials. PloS One; 2010.5:e14433. DOI: 10.1371/journal.pone.0014433
15. Brew BJ. The peripheral nerve complication of human immunodeficiency virus (hiv) infection. Muscle Nerve; 2003:28:542-552
16. Malessa R, Agelink M, Himmelmann M, Kloss T, Mertins L, Brockmeyer N. Nerve conduction changes in asymptomatic hiv-1 seropositive individuals in the absence of other risk factors for neuropathy. Electromyogr Clin Neurophysiol; 1996:26:3-8. PubMed:
diabetic peripheral neuropathy. Clinical Neurology and Neurosurgery 108; 2006.477-81. DOI: 10.1016/j.clineuro.2005.08.003
29. Craig BA., Strauss MB, Daniller A, Miller SS. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. Wounds; 2016.26(8):221-31. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25860638
30. Ponirakis G, Odriozola MN, Odriozola S, Petropoulos IN, Azmi IN, Fadavi H, et. al. NerveCheck: an inexpensive quantitative sensory testing device for patients with diabetic neuropathy. International Diabetes Federation. Diabetes Res Clin Pract; 2016. DOI: 10.1016/j.diabres.2015.12.023
31. Dubey TN, Raghubanshi SS, Sharma H, Saxena R. HIV neuropathy in pre-haart patients and it’s correlation with risk factors in central india. Neurology India; 2013.61(5):478-80. DOI: 10.4103/0002-3886.121912
32. Sithinamuwann P, Punthanamongkol S, Valcour V, Onsanit S, Nidhinandana S, Thitivichianalert S, et. al. Frequency and characteristic of h-assoicated sensory neuropathy among hiv patients in bangkok, thailand. J Acquir Immune Defic Syndr; 2008.49(4):456-58. DOI: [10.1097/QAI.0b013e318186eb03]
33. Konchalard K, Wangphonpattanasiri K. Clinical and electrophysiologic evaluation of peripheral neuropathy in a group of hiv-infected patients in thailand. J Med Assoc Thai; 2007.90(4):774-80
34. Luma HN, Tchaleu BCN, Doualla MS, Temfack E, Sopouassi VNK, Mapoure YN, et al. Hiv-associated sensory neuropathy in hiv-1 infected patients at the douala general hospital in cameroon: a cross sectional study. AIDS Research and Therapy; 2012.9:35. DOI: [10.1186/1742-6405-9-35]
35. Cettomai D, Kwasam JK, Birbeck GL, Price RW, Cohen CR, Bukusi E.A., et al. Screening for hiv-associated peripheral neuropathy in resource-limited setting. Muscle Nerve; 2013.48:516-24. DOI: [10.1002/mus.23795]
36. Nienov OH, Dias LS, Parisi MCR, Schmid H. Sensitivity and specificity of diabetic neuropathy diabetes score, neuropathy symptoms score, diabetic neuropathy score and esthesiometry compared with the gold standards michigan neuropathy screening instrument (mnsi) and beck depression inventory (BDI); 2015.7 (Suppl 1):A196. DOI: [10.1186/1758-5996-7-S1-A199]
37. Woldeamanuel YW, Kamerman PR, Veliotes DG, Phillips TJ, Asboe D, Boffito M, et. al. Development, validation, and field-testing of an instrument for clinical assessment of h-assoicated neuropathy and neuropathic pain in resource-restricted and large population study settings. clinical hiv-associated neuropathy tool (chant); 2016. DOI: 10.1371/journal.pone.0164994
38. Meijer JWG, Smit AJ, Lefrandt JD, Van Der Hoeven IN, Links T, Boeijink IN, Van Der Hoeven JH, Hoogenberg K, Links TP. Back to basics in diagnosing diabetic polyneuropathy with the tuning fox. diabetes care; 2005.28:2201-5. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16123490
39. Govind BT, Jyoti KT, Prakash MS, Milind VB. Clinical and electrophysiologic evaluation of peripheral neuropathy in hiv infected patients. https://www.ncbi.nlm.nih.gov/pubmed/8654319
17. Barohn R, Gronseth G, Amato A., et al. Cerebrospinal fluid and nerve conduction abnormalities in hiv positive individuals. J Neurol Sci; 1996.136:81-5
18. Phillips TJC, Brown M, Ramirez JD, Perkins J, Woldeamanuel YW, Williams AC.de C, et al. Sensory, psychological, and metabolic dysfunction in h-assoicated peripheral neuropathy: a cross sectional deep profiling study. PAIN; 2014.155:1846-60. DOI: 10.1016/j.pain.2014.06.014
19. Cettomai D, Kwasa J, Kendi C, Birbeck GL, Price RW, Bukusi E.A, et al. Utility of quantitive sensory testing and screening tools in identifying h-assoicated peripheral neuropathy in western kenya: pilot testing. PLoS One; 2010.5:e14256. DOI: 10.1371/journal.pone.0014256
20. Nebuchennykh M, Loseth S, Lindal S, Mellgren SI. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J Neurol; 2009.256:1067-75. DOI: 10.1007/s00415-009-5065-y
21. Simpson DM, Kitch D, Evans SR, et. al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology; 2006.66(11): 1679-87. DOI: 10.1212/01.wnl.0000218303.48113.5d
22. United States Department of Veteran Affairs. Peripheral Neuropathy and HIV – HIV/AIDS. http://www.hiv.va.gov/provider/manual-primary-care/peripheral-neuropathy-tool-1as1. 2010.
23. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the neuroscreen. J Neurovirol; 2005.11(6): 503-11. DOI: 10.1080/13550280500384966
24. Muntean C, Cătălin B, Tudorică V, Moţa M. Efficiency of michigan neuropathy screening instrument and nerve conduction studies for diagnosis of diabetic distal symmetric polyneuropathy. Rom J Diabetes Nutr Metab Dis; 2016.23(1):055065. DOI: 10.1515/rjndm-2016-0007
25. Bril V, Tomioka S, Buchanan RA, Perkins BA. Complications reliability and validity of the modified toronto clinical neuropathy score in diabetic sensorimotor polyneuropathy. journal compilation. diabetes uk. Diabetic Medicine; 2009.26:240–246. DOI: 10.1111/j.1464-5491.2009.02667.x
26. Mete T, Aydin Y, Saka M, Yayuv HC, Bilen S, Yalcin Y, et al. Comparison of efficiencies of michigan neuropathy screening instrument, neurothesiometer, and electromyography for diagnosis of diabetic neuropathy. International Journal of Endocrinology: 821745. 2013. DOI: 10.1155/2013/821745
27. Herman WH, Pop-Busui R, Braffet BH, Martin cl, cleary pa, albers jw et al. use of the michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med; 2012.29(7): page 937-944. DOI: 10.1111/j.1464-5491.2012.03644.x
28. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of michigan neuropathy screening instrument for
Purbasari B, Anggraini VA, Pratiwi MD, Husna M, Kurniawan SN. Diagnostic test of toronto and modified toronto scoring, monofilament test, and vibrate sensation test using 128 Hz tuning fork for diabetic polyneuropathy. Malang Neurology Journal; 2018.4:25-34. DOI: 10.21776/ub.mnj.2018.004.01.5